The azalide antibacterial agent azithromycin is a semisynthetic acid-stable erythromycin derivative with an expanded spectrum of activity and improved tissue pharmacokinetic characteristics relative to erythromycin. The drug is noted for its activity against some Gram-negative organisms associated with respiratory tract infections, particularly Haemophilus influenzae. Azithromycin has similar activity to other macrolides against Streptococcus pneumoniae and Moraxella catarrhalis, and is active against atypical pathogens such as Legionella pneumophila, Chlamydia pneumoniae and Mycoplasma pneumoniae.
Once-daily administration of azithromycin is made possible by the long elimination half-life of the drug from tissue. Azithromycin is rapidly and highly concentrated in a number of cell types after absorption, including leucocytes, monocytes and macrophages. It undergoes extensive distribution into tissue, from where it is subsequently eliminated slowly.
A 3-day oral regimen of once-daily azithromycin has been shown to be as effective as 5- to 10-day courses of other more frequently administered antibacterial agents [such as erythromycin, amoxicillin-clavulanic acid and Phenoxymethylpenicillin (penicillin V)] in patients with acute exacerbations of chronic bronchitis, pneumonia, sinusitis, pharyngitis, tonsillitis and otitis media. Adverse effects of azithromycin are mainly gastrointestinal in nature and occur less frequently than with erythromycin.
Azithromycin is likely to prove most useful as a 3-day regimen in the empirical management of respiratory tract infections in the community. Its ease of administration and 3-day duration of therapy, together with its good gastrointestinal tolerability, should optimise patient compliance (the highest level of which is achieved with once-daily regimens). Azithromycin is also likely to be useful in the hospital setting, particularly for outpatients and for those unable to tolerate erythromycin.
Overview of in Vitro Antibacterial Activity
Azithromycin has a similar spectrum of activity to erythromycin but is particularly noted for its activity against a number of Gram-negative organisms. On the basis of in vitro data, azithromycin is more active than erythromycin, clarithromycin and roxithromycin against Haemophilus influenzae. Azithromycin shows similar activity to erythromycin, clarithromycin and roxithromycin against Moraxella catarrhalis (with good activity against β-lactamase-positive strains of this organism) and Streptococcus pneumoniae.
Clinical isolates of Legionella pneumophila and Chlamydia pneumoniae are susceptible to azithromycin. In particular, the drug is very active against Mycoplasma pneumoniae, with in vitro data from 1 study showing the mean minimum drug concentration required to inhibit 90% of strains (MIC90) for erythromycin, clarithromycin and roxithromycin to be at least 32.5 times greater than that for azithromycin.
Erythromycin-susceptible strains of Staphylococcus aureus and most streptococci are susceptible to azithromycin, and the drug has shown good activity against S. pyogenes in studies conducted in vitro. Streptococcal and staphylococcal species that are resistant to erythromycin are also likely to be resistant to azithromycin, as are methicillin-resistant strains of S. aureus.
Overview of Pharmacokinetic Properties
Oral administration of azithromycin 500mg produces a peak serum concentration of approximately 0.4 to 0.45 mg/L after 2.5 hours. The drug is rapidly and highly concentrated in white blood cells and macrophages, undergoes extensive tissue distribution and achieves high concentrations in pulmonary and tonsillar tissue.
Azithromycin is largely eliminated unchanged via the faecal route, although some hepatic metabolism does occur. Polyphasic elimination reflects the initial rapid distribution of the drug into tissue and its subsequent slow elimination therefrom. A mean terminal serum elimination half-life of 57 hours has been reported for azithromycin.
Therapeutic Efficacy of 3-Day Azithromycin in Respiratory Tract Infections
Results of comparative trials have shown similar clinical efficacy for 3-day regimens of azithromycin and 5- to 10-day courses of other antibacterial drugs, including amoxicillin-clavulanic acid, erythromycin, clarithromycin, roxithromycin and josamycin in patients with acute bronchitis, acute exacerbations of chronic bronchitis or pneumonia. Combined rates of clinical cure and clinical improvement (cure plus improvement) 10 to 14 days after the start of therapy were similar for azithromycin and amoxicillin-clavulanic acid in patients with infections caused mainly by S. pneumoniae, H. influenzae or M. catarrhalis. Bacteriological efficacy (based on the eradication or presumed eradication of infecting pathogens) varied between trials but was similar for azithromycin and the comparator agent in most studies.
Azithromycin administered once a day for 3 days was as effective as a 5-day regimen of the drug in 84 patients with pneumonia caused by atypical pathogens such as M. pneumoniae, C. psittaci or Coxiella burnetii. Most studies in lower respiratory tract infections involved adults, but some paediatric data are also available.
Clinical cure plus improvement rates of 93 to 100% were reported in studies of patients (including children) with upper respiratory tract infections (acute pharyngitis, tonsillitis, sinusitis or otitis media) who received 3-day courses of azithromycin. Similar cure plus improvement rates were observed after 7- to 10-day courses of erythromycin, clarithromycin, roxithromycin, Phenoxymethylpenicillin (penicillin V), amoxicillin (with or without clavulanic acid) and cefaclor in these trials.
Pooled tolerability data from phase II and III studies of 3995 patients aged from 2 to 94 years showed orally administered azithromycin to be associated predominantly with gastrointestinal and central and peripheral nervous system adverse events (most of the patients who were included had received a total dose of azithromycin 1500mg over 5 days). The gastrointestinal tolerability of azithromycin was superior to that of erythromycin in this analysis.
A further analysis of tolerability data from clinical trials which involved 1129 children and young adults, 606 of whom received azithromycin (544 received the 3-day regimen), showed an incidence of adverse events of 7.6% for azithromycin and 13.8% overall for other antibacterial drugs, including amoxicillin, Phenoxymethylpenicillin, erythromycin and flucloxacillin. Gastrointestinal adverse events were reported significantly less frequently by azithromycin recipients than by those receiving other drugs.
Pooled data from 43 studies in 4499 children (aged 6 months to 16 years) who received 3-day azithromycin showed similar overall tolerability for azithromycin and a number of penicillins, cephalosporins and macrolides.
Azithromycin has not been associated with any clinically significant biochemical or haematological abnormalities.
Azithromycin does not interact with the hepatic cytochrome P450 system and is not associated with the pharmacokinetic drug interactions seen with erythromycin and other macrolides. The drug does not appear to affect metabolism of theophylline, carbamazepine, midazolam or terfenadine. Furthermore, the anticoagulant effect of a single 15mg dose of warfarin was not affected by concurrent therapy with azithromycin.
Serum cyclosporin and digoxin concentrations should be monitored when either of these 2 agents is given during treatment with azithromycin. Concurrent administration of the drug with ergot derivatives should be avoided.
Dosage and Administration
An oral dose of azithromycin 500mg should be given once daily for 3 days in upper and lower respiratory tract infections. Children aged over 6 months who weigh less than 45kg should receive 10 mg/kg once daily for 3 days. No dosage recommendations have been made for children aged under 6 months. Although it is recommended that azithromycin capsules are taken 1 hour before or 2 hours after food, recent data indicate that this is not necessary with the oral suspension and a novel tablet formulation of the drug.
KeywordsErythromycin Otitis Medium Clarithromycin Acute Otitis Medium Lower Respiratory Tract Infection
Unable to display preview. Download preview PDF.
- 4.Fass RJ. In vitro activity of Bay y 3118, a new quinolone. Anti-microb Agents Chemother 1993 Nov; 37: 2348–57Google Scholar
- 6.Hussain Qadri SM, Ueno Y, Tulio D, et al. In vitro activity of azithromycin: a long-acting azalide. Ann Saudi Med 1994 Mar; 14: 122–4Google Scholar
- 15.Urbášková P, Trupl J, Hupková H, et al. In vitro susceptibility of penicillin-susceptible and resistant pneumococci from central Europe to penicillin G, CP99.219, ciprofloxacin, Sparfloxacin, clindamycin, Cefpodoxime, erythromycin and azithromycin [abstract no. 306]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26–30; Vienna, 59.Google Scholar
- 27.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fifth informational supplement. Pennsylvania: NCCLS, 1994. NCCLS document M100-S5Google Scholar
- 28.Jones RN. Disk diffusion susceptibility testing of macrolides: the interpretive criteria. In: Bryskier AJ, Butzler J-P, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 209–15Google Scholar
- 30.Neu HC. Otitis media: antibiotic resistance of causative pathogens and treatment alternatives. Pediatr Infect Dis J 1995 Apr; 14(4) Suppl.: 51–6Google Scholar
- 40.Baldwin DR, Ashby JR, Andrews JM, et al. Pulmonary disposition of azithromycin following a single 500 mg oral dose [abstract]. Thorax 1990 Apr; 45: 324PGoogle Scholar
- 42.Shepard RM, Weidler DJ, Garg DC, et al. Human pharmacokinetics of azithromycin (CP-62,993/XZ-450), a new macrolide with an extended half-life and high tissue penetration. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1987 Oct 4–7; New York, 138Google Scholar
- 48.Paulsen O. Roxithromycin — a macrolide with improved pharmacokinetic properties. Drugs Today 1991; 27(3): 193–222Google Scholar
- 62.Rodriguez-Solares A, Pérez-Gutiérrez F, Prosperi J. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 103–9PubMedGoogle Scholar
- 69.Gwaltney Jr JM. Acute bronchitis. In: Mandell GL, Gordon Douglas Jr R, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 529–31Google Scholar
- 70.Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Gordon Douglas Jr R, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 531–5Google Scholar
- 71.Donowitz GR, Mandell GL. Acute pneumonia. In: Mandell GL, Gordon Douglas Jr R, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 540–55Google Scholar
- 72.Franckart G, Waelbroeck A, Demol P, et al. Azithromycin vs erythromycin in the treatment of lower respiratory tract infections in children [abstract]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26–30; Vienna, 269.Google Scholar
- 73.Principi N, Marchisio P, Biasini G, et al. Azithromycin versus erythromycin in the treatment of paediatric community-acquired pneumonia. Eur J Clin Res 1993; 4: 127–33Google Scholar
- 74.Ronchetti R, Blasi F, Grossi E, et al. The role of azithromycin in treating children with community-acquired pneumonia. Curr Ther Res 1994 Aug; 55: 965–70Google Scholar
- 76.Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother. In pressGoogle Scholar
- 78.Hoepelman IM, Möllers MJ, Van Schie MH, et al. Azithromycin (A) tablets for 3 days versus 10 days Augmentin (Aug) in adults with lower respiratory tract infection [abstract no. 764]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30; Vienna, 148Google Scholar
- 79.Zachariah J. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav for the treatment of adult patients with lower respiratory tract infections. J Antimicrob Chemother. In pressGoogle Scholar
- 80.Mertens JCC, van Barneveld PWC, Asin HRG, et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1992 Jul; 36: 1456–9PubMedGoogle Scholar
- 81.Laurent K. Efficacy, safety and toleration of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother. In pressGoogle Scholar
- 86.Pichichero ME. Therapeutic considerations for management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 1992; 6(3): 167–74Google Scholar
- 92.O’Doherty B. Azithromycin versus penicillin V in the treatment of pediatric patients with acute pharyngitis/tonsillitis [abstract no. 1388]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30; Vienna, 269.Google Scholar
- 94.Müller O. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J Antimicrob Chemother. In pressGoogle Scholar
- 96.O’Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. In pressGoogle Scholar
- 97.Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of paediatric patients with acute otitis media. J Antimicrob Chemother. In pressGoogle Scholar
- 98.Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991 Sep 12; 91 Suppl. 3A: 40–5Google Scholar
- 100.Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother. In pressGoogle Scholar
- 101.George J, Farrell GC. Role of human hepatic cytochromes P450 in drug metabolism and toxicity. Aust NZ J Med 1991; 21(3): 356–62Google Scholar
- 102.von Rosenstiel N-A, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 1995 Aug; 13(2): 105–22Google Scholar
- 103.Gardner MJ, Coates PE, Hilligoss DM, et al. Lack of effect of azithromycin on the pharmacokinetics of theophylline in man. Proceedings of the 8th Mediterranean Congress of Chemotherapy; 1992 May 24-29; AthensGoogle Scholar
- 104.Clauzel AM, Visier S, Michel FB. Efficacy and safety of azithromycine in lower respiratory tract infections [abstract]. Eur Respir J 1990 Sep; 3 Suppl. 10: 89Google Scholar
- 106.Rapeport WG, Dewland PM, Muirhead DC, et al. Lack of an interaction between azithromycin and carbamazepine [abstract]. Br J Clin Pharmacol 1992 May; 33: 55 IPGoogle Scholar
- 108.Zimmermann T, Laufen H, Yeates RA. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam [abstract no. 777]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26-30; Vienna, 151Google Scholar
- 109.Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron 1995 May; 70: 130Google Scholar
- 110.Association of the British Pharmaceutical Industry. Zithromax. In: Walker G, editor. ABPI Data Sheet Compendium 1994–95. London: Datapharm Publications Ltd., 1994: 1285–6Google Scholar
- 111.Foulds G, Luke DR, Teng R, et al. Food does not affect the bioavailability of azithromycin tablets, sachet, or suspension. J Antimicrob Chemother. In pressGoogle Scholar
- 112.Schentag JJ. Antibiotic treatment of acute otitis media in children: dosing considerations. Pediatr Infect Dis J 1995; 14(4): S30–33Google Scholar
- 114.Place in therapy of the newer macrolides: clarithromycin and azithromycin. Drug Ther Perspect 1993 Jan 25; 1 1: 5-7Google Scholar
- 118.Pfizer on Zithromax cost. Scrip Mag 1995 Jul 4 (2039): 23Google Scholar
- 119.American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26Google Scholar
- 120.Eron JJJ, Burkle W, Cohen MS. Managing pneumonia: defining the role of the new macrolide antibiotics. Hosp Formul 1994 Feb; 29: 122–36Google Scholar